DxTerity
Rancho Dominguez
About DxTerity
DxTerity Diagnostics is focused on simplifying genomic testing -- bringing the power of personalized medicine to routine medical care. The DxTerity technology, DxDirectTM, is a simple, fast and affordable technique for analysis of complex gene signatures. DxDirectTM combines a robust chemical ligation process, NEATTM , and a unique sample stabilization system, DxCollectTM. This enable direct from whole blood or tissue sample multiplex gene expression testing without many of the constraints that exist today. Testing which once could only be done by a sophisticated research lab, or highly specialized and high skilled area within a clinical lab, can now be performed reliably in a routine manner by lab technicians and clinicians, all with the same level of quality. Specialties-Molecular Diagnostics, Oncology, Immune Response
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $3.8M
- Last round: Series Unknown (Oct 2021)
- Website: dxterity.com
- Phone: +1 3103563154
Industries & Categories
Biotechnology, Genetics, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/dxterity-175439 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.